Orotirelin

Summary

Orotirelin (CG‑3703) is a synthetic analogue of thyrotropin‑releasing hormone (TRH) engineered for resistance to enzymatic breakdown. It is an approved prescription peptide that can be given intravenously or orally. Pre‑clinical studies show it modulates central neurotransmitter systems, influences prolactin release, and improves wakefulness and survival in animal models of narcolepsy and traumatic brain injury.

Mechanism of Action

Orotirelin binds to TRH receptors (mainly TRH‑R1) on neurons and pituitary cells, activating G‑protein‑coupled phospholipase C signaling, raising intracellular IP₃ and Ca²⁺, and triggering release of downstream mediators such as thyrotropin, prolactin, noradrenaline and serotonin. Its peptidase resistance prolongs receptor engagement, allowing sustained modulation of noradrenergic, serotonergic and dopaminergic pathways that underlie its arousal‑promoting and endocrine effects.

What the Research Shows

Animal investigations have explored orotirelin’s pharmacology across several systems. In iron‑deficient rats, the peptide did not alter hypothermic or motor responses to d‑amphetamine, suggesting limited interaction with dopaminergic thermoregulation under those conditions. In vitro pituitary assays demonstrated that orotirelin can both stimulate prolactin release in the presence of low dopamine and inhibit it indirectly via dopamine release, indicating a bidirectional influence on lactotroph activity. Neuropharmacological screens reported antidepressant‑like activity, reversal of central depressant effects, and promotion of arousal, with potency exceeding native TRH. Chronic oral dosing in a canine model of narcolepsy produced dose‑dependent reductions in cataplexy and daytime sleep without measurable changes in cardiovascular, metabolic, or thyroid parameters, though tolerance developed after one week. Additional rodent work reported improved survival after traumatic brain injury and modulation of noradrenergic and serotonergic transmission, supporting a broad neuromodulatory profile.

Reported Benefits

Orotirelin has shown several experimental benefits: it enhances wakefulness and reduces cataplexy in a canine narcolepsy model; it can stimulate prolactin release under specific dopaminergic conditions; it improves survival and functional outcome after traumatic brain injury in rats; and it exerts antidepressant‑like effects and reverses depressant‑induced sedation in neurobehavioral tests. Its resistance to enzymatic breakdown yields a longer biological half‑life compared with native TRH, potentially allowing more sustained therapeutic action.

Limitations of the Evidence

Evidence for orotirelin is confined to animal experiments; no controlled human trials are cited. Effects on thermoregulation and motor activity were absent in iron‑deficient rats, indicating context‑dependent efficacy. Tolerance to wake‑promoting effects emerged after one week of dosing in dogs, suggesting limited durability. The prolactin findings are complex, showing both stimulation and inhibition, and may not translate clinically. Overall, the therapeutic relevance of the observed neurochemical changes remains uncertain without clinical outcome data.

Safety Considerations

Safety observations from the canine narcolepsy study reported no significant alterations in heart rate, blood pressure, body temperature, routine blood chemistry, or thyroid hormone levels during acute or two‑week oral treatment. Rodent studies did not describe overt toxicity, and the peptide’s peptidic nature generally confers low immunogenicity. However, the development of tolerance to its wake‑promoting effects was noted, and the absence of systematic adverse‑event reporting in the pre‑clinical literature warrants caution when extrapolating to humans.

How It Is Administered

Orotirelin can be administered intravenously or orally. In pre‑clinical work, intravenous dosing (≈1 mg/kg) was used to assess acute neuroendocrine effects, while oral formulations (0.25–16 mg/kg) demonstrated dose‑dependent activity in canine narcolepsy models. The peptide is supplied as a solution for injection or as oral tablets/capsules, reflecting its approved prescription status.

Routes of Administration

Goals & Uses

• Prolactin stimulation testingEndocrinologyModerate
• Diagnostic evaluation of hypothalamic-pituitary-thyroid axisDiagnosticsHigh
• NeuroprotectionNeurologyLow
• Assessment of spinocerebellar degenerationNeurologyModerate

Contraindications

• HyperthyroidismEndocrineModerate
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Coronary artery diseaseCardiovascularHigh
• Hypersensitivity to orotirelin or TRH analoguesAllergyHigh

Adverse Effects

• Urge to urinateUrologicalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• FlushingVascularCommonWarmth and redness of the skin
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Transient hypotension or hypertensionCardiovascularUncommon

Drug Interactions

• GlucocorticoidsLow
• Thyroid hormones (levothyroxine)Moderate
• Dopamine agonists (bromocriptine, cabergoline)Low

Population Constraints

• Pediatric patientsAgeRelative
• Elderly patientsAgeRelative
• Patients with severe cardiovascular diseaseCardiovascularRelative

Regulatory Status

• European UnionUnapprovedNot approved by the EMA for use in the European Union
• United StatesUnapprovedNot approved by the FDA; not available as a licensed product in the United States
• United KingdomUnapprovedNot approved by the MHRA in the United Kingdom

Approved in Japan as a diagnostic and therapeutic agent. Not approved by the FDA in the United States or by the EMA in Europe.

Evidence & Sources

• Iron deficiency induces reversal of dopamine dependent circadian cycles: differential response to d-amphetamine and TRH
  Journal ArticleLowYoudim MB, Yehuda S1985-01-01T00:00:00.000000Z
• Regulatory peptides as a source of new drugs--the clinical prospects for analogues of TRH which are resistant to metabolic degradation
  Journal ArticleModerateMetcalf G1982-01-01T00:00:00.000000Z
• Effect of the TRH analogue, CG 3703, on prolactin secretion in the pseudopregnant rat
  Journal ArticleLowSchuiling GA, et al.1993-01-01T00:00:00.000000Z
• Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy
  Journal ArticleLowRiehl J, et al.2000-01-01T00:00:00.000000Z
• Beneficial effect of the TRH analog CG-3703 on outcome and survival following traumatic brain injury in rats
  Journal ArticleLowMcIntosh TK, Vink R, Faden AI1988-01-01T00:00:00.000000Z
• Effects of the thyroliberin analogue CG 3703 on noradrenergic and serotoninergic transmission in rodents
  Journal ArticleLowHennies HH, Flohé L1982-01-01T00:00:00.000000Z

Frequently Asked Questions